Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease

NCT04846036 is registered in ClinicalTrials.gov with Khondrion BV as lead sponsor.

NCT NCT04846036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04846036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease
Lead sponsor
Khondrion BV
Phase
Phase 2
Overall status
Suspended
Start date
February 1, 2021
Completion date
December 1, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melas, mitochondrial diseases, mitochondrial dna trnaleu(uur) m.3243a<g mutation, subacute necrotizing encephalomyelopathy